JAZZ Jazz Pharmaceuticals plc

Price (delayed)

$133.96

Market cap

$8.19B

P/E Ratio

120.68

Dividend/share

N/A

EPS

$1.11

Enterprise value

$14.19B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
Jazz Pharmaceuticals's equity has increased by 32% YoY and by 9% from the previous quarter
The revenue has grown by 18% YoY and by 8% from the previous quarter
Jazz Pharmaceuticals's net income has shrunk by 92% QoQ and by 70% YoY
The company's EPS has shrunk by 88% QoQ and by 53% YoY

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
61.15M
Market cap
$8.19B
Enterprise value
$14.19B
Valuations
Price to earnings (P/E)
120.68
Price to book (P/B)
1.84
Price to sales (P/S)
3.03
EV/EBIT
30.29
EV/EBITDA
17.06
EV/Sales
5.41
Earnings
Revenue
$2.63B
EBIT
$468.65M
EBITDA
$832.1M
Free cash flow
$768.28M
Per share
EPS
$1.11
Free cash flow per share
$12.92
Book value per share
$72.61
Revenue per share
$44.17
TBVPS
$62.87
Balance sheet
Total assets
$13.21B
Total liabilities
$9.08B
Debt
$6.89B
Equity
$4.13B
Working capital
$2.07B
Liquidity
Debt to equity
1.67
Current ratio
3.35
Quick ratio
1.59
Net debt/EBITDA
7.21
Margins
EBITDA margin
31.7%
Gross margin
90.4%
Net margin
1.5%
Operating margin
17.6%
Efficiency
Return on assets
0.5%
Return on equity
1.1%
Return on invested capital
9.5%
Return on capital employed
3.8%
Return on sales
17.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-2.48%
1 week
-8.04%
1 month
0.1%
1 year
-10.43%
YTD
-18.84%
QTD
2.88%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$2.63B
Gross profit
$2.37B
Operating income
$462.15M
Net income
$40.16M
Gross margin
90.4%
Net margin
1.5%
The operating income has surged by 128% year-on-year but it has declined by 37% since the previous quarter
JAZZ's operating margin has soared by 93% year-on-year but it is down by 41% since the previous quarter
The company's net margin has shrunk by 93% QoQ and by 75% YoY
Jazz Pharmaceuticals's net income has shrunk by 92% QoQ and by 70% YoY

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
120.68
P/B
1.84
P/S
3.03
EV/EBIT
30.29
EV/EBITDA
17.06
EV/Sales
5.41
The company's EPS has shrunk by 88% QoQ and by 53% YoY
The P/E is 85% higher than the last 4 quarters average of 65.1
The price to book (P/B) is 37% lower than the 5-year quarterly average of 2.9 and 23% lower than the last 4 quarters average of 2.4
Jazz Pharmaceuticals's equity has increased by 32% YoY and by 9% from the previous quarter
The price to sales (P/S) is 31% less than the 5-year quarterly average of 4.4 and 20% less than the last 4 quarters average of 3.8
The revenue has grown by 18% YoY and by 8% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The company's return on sales has surged by 105% YoY but it fell by 40% QoQ
The company's return on assets has shrunk by 94% QoQ and by 79% YoY
The return on equity has dropped by 93% since the previous quarter and by 75% year-on-year
JAZZ's ROIC has shrunk by 52% QoQ but it is up by 48% YoY

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 45% greater than the total liabilities
The total assets has soared by 118% year-on-year and by 96% since the previous quarter
Jazz Pharmaceuticals's quick ratio has plunged by 68% YoY and by 58% from the previous quarter
The company's debt is 67% higher than its equity
Jazz Pharmaceuticals's debt to equity has surged by 183% QoQ and by 132% YoY
Jazz Pharmaceuticals's equity has increased by 32% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.